3 Japanese Stocks Screening Cheap on Cash Flow Right Now

Global bond yields are climbing as inflation concerns keep borrowing costs elevated for governments and companies. That kind of fixed income selloff often pushes investors to look harder at equity valuations and cash generation. Undervalued Stocks Based On Cash Flows takes advantage of this by flagging companies where discounted cash flow values sit above current prices. This article highlights three stocks that currently screen as undervalued on that basis.

The three stocks below are just a starting sample, and the same cash flow screen currently identifies 62 more companies with equally compelling stories that are not covered here. To go straight to the source, analyze and compare opportunities directly in the Undervalued Stocks Based On Cash Flows screener.

Chugai Pharmaceutical (TSE:4519)

Overview: Chugai Pharmaceutical is a Japan based drug company focused on oncology and specialty biologic medicines such as Alecensa, Avastin, Herceptin, Perjeta, Kadcyla, Polivy and Vabysmo, which are designed for cancer and other serious diseases and are often sold globally through its Roche partnership. Alongside this high value biologics portfolio, Chugai also sells a wider range of therapies for autoimmune, infectious and rare conditions.

Operations: Chugai generates essentially all of its ¥1,342,808 million revenue from pharmaceuticals, with sales split between Japan and overseas markets.

Market Cap: ¥11,265.4 billion

Investors looking at cash flow driven value ideas may find Chugai Pharmaceutical interesting because its oncology and specialty biologics portfolio typically produces high margin, relatively predictable cash flows that underpin discounted cash flow models, yet the stock is currently screening around 41.5% below the SWS fair value estimate. The company reported half year 2026 revenue of ¥663,331 million and net income of ¥231,749 million, which aligns with that cash generation profile and a higher Q2 2026 dividend of ¥66 per share. At the same time, heavy dependence on a handful of blockbuster biologics and pricing or regulatory pressure creates risk for future cash flows. The key question is whether the oncology pipeline and Roche collaboration can sustain that cash engine long enough to close the gap.

Chugai Pharmaceutical’s cash engine and Roche partnership may be masking an even bigger valuation gap than headline metrics suggest. Get the full context and understand the hidden risks in the 3 key rewards and 1 important warning sign

Build your own cash flow shortlist around Chugai Pharmaceutical

Chugai Pharmaceutical and the other two stocks in this article all came from a single screener, but the real value for you is in setting your own rules. Use our customisable Screener to mix filters like cash flows, valuation, balance sheet strength and risks, or jump straight into our curated Investing Ideas for ready made shortlists.

Recruit Holdings (TSE:6098)

Overview: Recruit Holdings runs global online hiring platforms such as Indeed and Rikunabi alongside large staffing and marketing matching businesses, helping employers and job seekers connect and transact. The HR Technology segment is central to its fit with the Undervalued Stocks Based On Cash Flows theme because subscription, job posting and placement fees can translate into relatively steady operating cash flows that underpin discounted cash flow valuations.

Operations: Recruit Holdings generates around ¥1.75 trillion in revenue from Staffing, ¥1.57 trillion from HR Technology and ¥569.7 billion from Marketing Matching Technologies, with a small unallocated adjustment of ¥28.4 billion.

Market Cap: ¥22.3 trillion

Recruit Holdings offers a combination of a large scale HR technology business, solid profitability and a stock that screens as trading at a sizeable discount to cash flow based fair value. The HR platforms are producing earnings with net income and return on equity metrics that support the idea of underlying cash generation, while recent guidance updates and buybacks indicate management confidence in that cash engine. A potential risk is that softer labor demand and pressure in international staffing could affect growth or increase earnings volatility. The key question for investors is how the HR Technology cash flows compare with those headwinds and whether the current discount accurately reflects that balance.

Recruit Holdings appears to be a cash flow engine trading at a discount, yet the real story lies in the details of its cash generation, segment mix and capital returns. Get the full picture in the analysis report for Recruit Holdings

Murata Manufacturing (TSE:6981)

Overview: Murata Manufacturing is a Japan based electronics company that supplies high volume ceramic capacitors, RF modules and other passive components used in communications, data centers, cars and consumer devices, which are key drivers of its recurring cash flows. Alongside this Components business, Murata also sells sensors, batteries and wireless solutions that broaden its reach across industrial, mobility and energy applications.

Operations: Murata generates most of its revenue from the Components segment at ¥1,250,550 million, with additional contributions from Devices and Modules at ¥664,774 million and a smaller Others segment at ¥71,492 million.

Market Cap: ¥13.6 trillion

Murata Manufacturing may appeal to cash flow focused investors because its high volume capacitors and RF modules are essential parts in 5G, data centers and automotive electronics, which supports recurring, high margin cash generation. The stock currently trades around 27.2% below the SWS DCF fair value estimate, so the market may not be fully pricing in that earnings power or the raised guidance for revenue of ¥2,110,000 million and operating profit of ¥430,000 million for the year to March 2027. At the same time, Murata remains exposed to swings in tech demand and pricing pressure in passive components. The key question is whether those core Components cash flows stay resilient enough for that valuation gap to matter.

Murata Manufacturing looks like a cash engine tied to 5G, data centers and autos, yet the current discount hints at something the market may be missing. Get the full story in the analysis report for Murata Manufacturing

Seeking Fresh Alternatives Before Others Do

Some stocks are already building breakout momentum while many investors remain focused on yesterday’s stories. Consider these fresh ideas while they are still under the radar.

• Identify companies quietly building strength in choppy markets by scanning a curated 60 resilient stocks with low risk scores list before the broader market takes notice.
• Explore opportunities in smart factories and automated logistics by reviewing a hand picked group of 37 robotics and automation stocks involved in evolving supply chains.
• Monitor the energy transition by tracking a focused basket of 93 nuclear energy infrastructure stocks while sentiment is still developing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com